Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Central Garden Pet

Has This Top 100 Stock to Buy Gone to the Dogs?

Highflying Dogness Corp. jumped more than 13% Monday, reentering Barchart’s Top 100 Stocks to Buy in the 61st spot. Up nearly 460% in 2024, the marketer of pet-related products has a nosebleed valuation at current price. FOMO is definitely in play here.

Barchart

Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022

Upgrades

Benzinga

Earnings Scheduled For May 4, 2022

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Liberty Latin America

11 stories

Toll Brors

11 stories

Adaptive Biotechnologies

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

372,857 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.